A randomised placebo-controlled trial of rivastigmine in delirium in older ... | Not Recruiting
A randomised placebo-controlled tri... | Not Recruiting
A randomised placebo-controlled trial of rivastigmine in delirium in older medical in-patients: a pilot study

Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Delirium
Prof Alistair Burns
See all trial contact details
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN27327721
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
Not provided at time of registration
Research Details
  • 1. The duration of delirium in people aged 65 or over on admission to an acute medical care of the elderly ward, or with onset at any time 3 weeks after admission, will be significantly less when treated with rivastigmine up to 3 mg daily compared to placebo, whether or not supplemented by risperidone 1 mg in divided doses daily
    2. The proportion of older people who develop a delirium postoperatively following an orthopaedic procedure will be significantly less when treated with rivastigmine up to 3 mg daily compared to placebo, whether or not supplemented by risperidone 1 mg in divided doses daily
    3. The percentage of patients who experience adverse events or complications on rivastigmine compared to placebo will be significantly less than those receiving treatment as usual
    4. The percentage of patients who relapse after three delirium-free days after an episode of delirium will be significantly higher in those previously treated as usual than those treated with rivastigmine
    5. These differences will remain significant irrespective of pre-admission cognitive function
Phase
Not Specified
Study Design
Randomised controlled trial
Study Type
Interventional
Intervention

Rivastigmine up to 1.5 mg twice a day or placebo.

Intervention Type
Drug
Primary Outcome Measures
    1. If develops delirium as found on Confusion Assessment Method
    2. Length of delirium, measured in days
Secondary Outcome Measures
    1. Length of admission
    2. Change in mini-mental state examination score
    3. Use of other psychotropic medication during treatment e.g. benzodiazepines
Publication(s)
2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20353624
Result Reports
Sorry, this information is not available
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
Senior
Who Can Participate
Patient
Number of Participants
50
Participant Inclusion Criteria
    1. Patients over 65 years old
    2. Admitted to elderly acute medical ward or orthopaedic ward
    3. Patient has a delirium as measured on the Confusion Assessment Method or doesn't have a delirium and has a fractured neck of femur caused by trauma
Participant Exclusion Criteria
    1. Patient already on cholinesterase inhibitor
    2. Patient has had a previous adverse reaction to a cholinesterase inhibitor
    3. If considered by medical team in charge of care to be in the terminal phase of illness
    4. Acute chronic obstructive pulmonary disease (COPD) or asthma
    5. Has a dysrhythmia on electrocardiogram (ECG)
    6. Urea >20 or creatinine >200
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Wythenshawe
M23 9LT
Trial Contact(s)
Primary Trial Contact
Prof Alistair Burns
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Sorry, this information is not available
EudraCT Number
Sorry, this information is not available
Funder(s)
  • Novartis (UK) - paid for tablets only
  • South Manchester University Hospitals NHS Trust (UK)
Other Study ID Numbers
3
Sponsor(s)
South Manchester University Hospitals NHS Trust (UK)
Key Dates

Recruitment Start Date

01 Apr 2004

Recruitment End Date

01 Jul 2006

Trial Start Date

01 Apr 2004

Trial End Date

01 Jul 2006

Date added to source

28 Oct 2005

Date updated in source

14 Jul 2010